Lorraine Marie Item
Research Subjects
Lorraine Marie Item has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aida Atiqah Mohamad Noor
B-Crobes Laboratory Sdn. Bhd, Ipoh, Malaysia, Malaysia
1 shared publication - Gretel G. Dema-Ala
Department of Pediatrics, Ospital ng Maynila Medical Center, Manila, Philippines, Philippines
1 shared publication - Hajar Fauzan Ahmad
Universiti Malaysia Pahang Al-Sultan Abdullah, Pekan, Malaysia, Malaysia
1 shared publication - Norain Mohd Tamsir
B-Crobes Laboratory Sdn Bhd, Ipoh, Malaysia, Malaysia
1 shared publication - Nur Zawani Ahmad Zahir
B-Crobes LAboatory Sdn Bhd, Ipoh, Malaysia, Malaysia
1 shared publication - Seok Fang Oon
B-Crobes Laboratory Sdn. Bhd., 18 & 20, Lintasan Perajurit 17g, Taman Perdagangan & Perindustrian Ipoh, Ipoh 31400, Perak, Malaysia
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Preprints.org
Probiotics in Paediatric Gut and Immune Health: Mechanisms and Clinical Evidence with a Focus on Microbial Cell Preparations
Background: Early-life gut microbiota plays a fundamental role in immune and metabolic development. Although probiotics have been widely investigated in paediatric populations, evidence regarding microbial cell preparation (MCP)-associated probiotic formulations, in which selected probiotic strains are incorporated into a standardized microbial preparation, remains fragmented. Objectives: This narrative review synthesizes current evidence on the potential role of MCP-associated strains in supporting gut health, immune modulation, and clinical outcomes in infants and children. Methods: A narrative literature review was conducted comprising peer-reviewed articles identified from major scientific databases. Grey literature, including unpublished conference presentations and institutional research materials, was also included. Studies were selected based on their relevance to the functional properties and clinical applications in paediatric populations. Results: Available evidence suggests that MCP-associated strains, including Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium infantis, contribute to improve gut barrier function, enrich healthy microbial composition, and modulate immune homeostasis through the production of short-chain fatty acids (SCFAs), bacteriocins, and exopolysaccharides. Clinical evidence has suggested potential benefits in growth outcomes among small-for-gestational-age (SGA) infants, reduction in the duration of certain infectious episodes, and prevention of selected neonatal and paediatric infections, with a favourable safety and tolerability profile. Conclusions: MCP-associated probiotic interventions may have potential roles as adjunctive therapies in paediatric care, supporting gut and immune health and contributing to the growing body of evidence in this field. Further multidisciplinary research is required to establish standardized protocols and strengthen the evidence base for microbiome-targeted therapeutics in children.
- 28 September 2026
- Published by MDPI AG in Preprints.org
Open AccessProbiotics in Paediatric Gut and Immune Health: Mechanisms and Clinical Evidence with a Focus on Microbial Cell Preparations
Background: Early-life gut microbiota plays a fundamental role in immune and metabolic development. Although probiotics have been widely investigated in paediatric populations, evidence regarding microbial cell preparation (MCP)-associated probiotic formulations, in which selected probiotic strains are incorporated into a standardized microbial preparation, remains fragmented. Objectives: This narrative review synthesizes current evidence on the potential role of MCP-associated strains in supporting gut health, immune modulation, and clinical outcomes in infants and children. Methods: A narrative literature review was conducted comprising peer-reviewed articles identified from major scientific databases. Grey literature, including unpublished conference presentations and institutional research materials, was also included. Studies were selected based on their relevance to the functional properties and clinical applications in paediatric populations. Results: Available evidence suggests that MCP-associated strains, including Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium infantis, contribute to improve gut barrier function, enrich healthy microbial composition, and modulate immune homeostasis through the production of short-chain fatty acids (SCFAs), bacteriocins, and exopolysaccharides. Clinical evidence has suggested potential benefits in growth outcomes among small-for-gestational-age (SGA) infants, reduction in the duration of certain infectious episodes, and prevention of selected neonatal and paediatric infections, with a favourable safety and tolerability profile. Conclusions: MCP-associated probiotic interventions may have potential roles as adjunctive therapies in paediatric care, supporting gut and immune health and contributing to the growing body of evidence in this field. Further multidisciplinary research is required to establish standardized protocols and strengthen the evidence base for microbiome-targeted therapeutics in children.